表紙
市場調查報告書

白斑症的全球市場:治療藥、主要企業、臨床研究、課題

Global Vitiligo Market, Patients By Countries (USA, UK, France, Germany, Italy, India, China, Japan), Drugs (ARN-4079, ATI-502, AX-1602, BOS-47, CCP-070, Cerdulatinib (RVT-502), HuABC-2, & Others) Companies, Clinical Study, Growth Drivers, Challenges

出版商 Renub Research 商品編碼 756444
出版日期 內容資訊 英文 100 Pages
商品交期: 最快1-2個工作天內
價格
白斑症的全球市場:治療藥、主要企業、臨床研究、課題 Global Vitiligo Market, Patients By Countries (USA, UK, France, Germany, Italy, India, China, Japan), Drugs (ARN-4079, ATI-502, AX-1602, BOS-47, CCP-070, Cerdulatinib (RVT-502), HuABC-2, & Others) Companies, Clinical Study, Growth Drivers, Challenges
出版日期: 2018年12月10日內容資訊: 英文 100 Pages
簡介

世界白斑症市場規模,預測至2024年將達到24億美元。

本報告提供全球白斑症治療藥市場相關調查,全球市場的患者人口、患者人口佔有率,及主要對各國的患者人口與市場規模,市場成長的推動要素與課題,研究開發趨勢,及主要企業簡介等資訊彙整。

第1章 簡介

第2章 分析方法

第3章 摘要整理

第4章 全球白斑症患者人口 & 市場

  • 白斑症患者人口
  • 白斑症市場

第5章 佔有率:全球白斑症患者人口 & 市場

  • 白斑症患者人口占有率
  • 白斑症市場佔有率

第6章 美國

  • 白斑症患者人口
  • 白斑症市場

第7章 英國

第8章 法國

第9章 德國

第10章 義大利

第11章 印度

第12章 中國

第13章 日本

第14章 開發平台藥物

  • ARN-4079
  • ATI-502
  • AX-1602
  • BOS-475
  • CCP-070
  • Cerdulatinib (RVT-502)
  • HuABC-2
  • Abatacept
  • Topical Ruxolitinib
  • VLRX-001

第15章 臨床研究

第16章 成長促進因素

  • 美觀魅力的重要性高漲
  • 全球白斑症日

第17章 全球白斑症市場:課題

  • 皮膚科醫生的不足
  • 可利用的治療不是很有效

第18章 AXIM Biotechnologies, Inc.

第19章 Incyte Corporation

第20章 Bristol-Myers Squibb

第21章 Clinuvel Pharmaceuticals Ltd

目錄

Title:
Global Vitiligo Market
Patients By Countries (United States, United Kingdom, France, Germany, Italy, India, China, Japan), Drugs (ARN-4079, ATI-502, AX-1602, BOS-47, CCP-070, Cerdulatinib (RVT-502), HuABC-2, Abatacept, Topical Ruxolitinib, VLRX-001) Companies (AXIM Biotechnologies, Incyte Corporation, Bristol-Myers Squibb, Clinuvel Pharmaceuticals), Clinical Study, Growth Drivers, Challenges.

Vitiligo is a long-term skin disease in which patches of the skin lose their color. The skin patches affected by the disease Vitiligo become white. This happens because melanocytes within the skin die off. The skin pigmentation, melanin, due to which skin has its color, protection from sun UV rays this all happens because of melanocytes cells. Growing per capita healthcare expenditure, improving healthcare infrastructure in developing countries, growing diseases awareness and expected approval of Vitiligo drugs are some of the driving force for the growth of this market. However, shortage of dermatologists and available treatments having longer duration of times are major challenges for the growth of this market. According to Renub Research global Vitiligo market will be US$ 2.4 Billion by the year 2024.

Vitiligo disease prevalence varies between race, regions and countries. It is expected that overall prevalence fall between 1-2 percent of the total population. Although Vitiligo disease can arise at any age, it mostly occurs to young and middle age people. At present globally over 21 Million people has suffered from this diseases. There are number of drugs manufactures working for Vitiligo drugs development across various parts of the globe such as AXIM Biotechnologies, Boston Pharmaceutical, Castle Creek Pharma, Dermavant Sciences, JN Biosciences, Bristol-Myers Squibb, Incyte Corporation, Clinuvel Pharmaceuticals etc. and their Vitiligo drugs development are in various stages.

Renub Research report titled "Global Vitiligo Market, Patients By Countries (United States, United Kingdom, France, Germany, Italy, India, China, Japan), Drugs (ARN-4079, ATI-502, AX-1602, BOS-47, CCP-070, Cerdulatinib (RVT-502), HuABC-2, Abatacept, Topical Ruxolitinib, VLRX-001) Companies (AXIM Biotechnologies, Incyte Corporation, Bristol-Myers Squibb, Clinuvel Pharmaceuticals), Clinical Study, Growth Drivers, Challenges" provides a complete analysis of global vitiligo drugs market.

India and China are Key Contributors in the Global Vitiligo Patient Population

Vitiligo patient's population is growing across all parts of the world. Patient's growth rates varies in the countries covered in the report United States, United Kingdom, France, Germany, Italy, India, China and Japan. India and China are key contributors in the global vitiligo patient population.

Vitiligo Pipe Line Drugs are Key Strength for this Market Place

In the global vitiligo market, vitiligo pipe line drugs will play the major role for the growth of this market. At present several drugs such as ARN-4079, ATI-502, AX-1602, BOS-47, CCP-070, Cerdulatinib (RVT-502), HuABC-2, Abatacept, Topical Ruxolitinib, VLRX-001 etc. are in preclinical, IND, Phase I, Phase II and Phase III stage.

Key Drugs Development Companies are working in this Market Place

Key drugs development companies are working in this market place across various parts of the globe such as AXIM Biotechnologies, Boston Pharmaceutical, Castle Creek Pharma, Dermavant Sciences, JN Biosciences, Bristol-Myers Squibb, Incyte Corporation, Clinuvel Pharmaceuticals etc.

Segments - Global Vitiligo Market:

  • Vitiligo Patients Population
  • Vitiligo Market

Countries - Global Vitiligo Market:

  • United States
  • United Kingdom
  • France
  • Germany
  • Italy
  • India
  • China
  • Japan

Global Vitiligo Market - Drugs Profile Covered:

  • ARN-4079
  • ATI-502
  • AX-1602
  • BOS-47
  • CCP-070
  • Cerdulatinib (RVT-502)
  • HuABC-2
  • Abatacept
  • Topical Ruxolitinib
  • VLRX-001

Companies Covered

  • AXIM Biotechnologies
  • Incyte Corporation
  • Bristol-Myers Squibb
  • Clinuvel Pharmaceuticals

Each Company Covered in this Report has Following Details:

  • Company Overview
  • Company Initiatives
  • Financial Insight

Table of Contents

1. Introduction

  • 1.1 Market Definition

2. Research Methodology

3. Executive Summary

4. Global Vitiligo Patient Numbers & Market

  • 4.1 Vitiligo Patients Numbers
  • 4.2 Vitiligo Market

5. Share - Global Vitiligo Patient Numbers & Market

  • 5.1 Vitiligo Patient Numbers Share
  • 5.2 Vitiligo Market Share

6. United States

  • 6.1 Vitiligo Patient Numbers
  • 6.2 Vitiligo Market

7. United Kingdom

  • 7.1 Vitiligo Patient Numbers
  • 7.2 Vitiligo Market

8. France

  • 8.1 Vitiligo Patient Numbers
  • 8.2 Vitiligo Market

9. Germany

  • 9.1 Vitiligo Patient Numbers
  • 9.2 Vitiligo Market

10. Italy

  • 10.1 Vitiligo Patient Numbers
  • 10.2 Vitiligo Market

11. India

  • 11.1 Vitiligo Patient Numbers
  • 11.2 Vitiligo Market

12. China

  • 12.1 Vitiligo Patient Numbers
  • 12.2 Vitiligo Market

13. Japan

  • 13.1 Vitiligo Patient Numbers
  • 13.2 Vitiligo Market

14. Vitiligo Pipe Line Drugs

  • 14.1 ARN-4079
  • 14.2 ATI-502
  • 14.3 AX-1602
  • 14.4 BOS-475
  • 14.5 CCP-070
  • 14.6 Cerdulatinib (RVT-502)
  • 14.7 HuABC-2
  • 14.8 Abatacept
  • 14.9 Topical Ruxolitinib
  • 14.10 VLRX-001

15. Clinical Study of Vitiligo Market

16. Growth Drivers

  • 16.1 Growing Importance of Aesthetic Appeal
  • 16.2 World Vitiligo Day: Increases Vitiligo Awareness

17. Global Vitiligo Market - Challenges

  • 17.1 Shortage of Dermatologists
  • 17.2 Available Treatments are Not Much Effective

18. AXIM Biotechnologies, Inc.

  • 18.1 Company Overview
  • 18.2 Initiatives
    • 18.2.1 Point 1
    • 18.2.2 Point 2
    • 18.2.3 Point 3
  • 18.3 Financial Insight

19. Incyte Corporation

  • 19.1 Company Overview
  • 19.2 Initiatives
    • 19.2.1 Point 1
    • 19.2.2 Point 2
  • 19.3 Financial Insight

20. Bristol-Myers Squibb

  • 20.1 Company Overview
  • 20.2 Initiatives
    • 20.2.1 Point 1
    • 20.2.2 Point 2
  • 20.3 Financial Insight

21. Clinuvel Pharmaceuticals Ltd

  • 21.1 Company Overview
  • 21.2 Company Initiatives
    • 21.2.1 Point 1
    • 21.2.2 Point 2
  • 21.3 Financial Insight

List of Figures:

Figure 4 1: Global - Vitiligo Patients Population (Thousand), 2012 - 2017

Figure 4 2: Global - Forecast for Vitiligo Patients Population (Thousand), 2018 - 2024

Figure 4 3: Global - Vitiligo Market (Million US$), 2012 - 2017

Figure 4 4: Global - Forecast for Vitiligo Market (Million US$), 2018 - 2024

Figure 5 1: Global - Vitiligo Patients Population Share (Percent), 2012 - 2017

Figure 5 2: Global - Forecast for Vitiligo Patients Population Share (Percent), 2018 - 2024

Figure 5 3: Global - Vitiligo Market Share (Percent), 2012 - 2017

Figure 5 4: Global - Forecast for Vitiligo Market Share (Percent), 2018 - 2024

Figure 6 1: United States - Vitiligo Patients Population (Thousand), 2012 - 2017

Figure 6 2: United States - Forecast for Vitiligo Patients Population (Thousand), 2018 - 2024

Figure 6 3: United States - Vitiligo Market (Million US$), 2012 - 2017

Figure 6 4: United States - Forecast for Vitiligo Market (Million US$), 2018 - 2024

Figure 7 1: United Kingdom - Vitiligo Patients Population (Thousand), 2012 - 2017

Figure 7 2: United Kingdom - Forecast for Vitiligo Patients Population (Thousand), 2018 - 2024

Figure 7 3: United Kingdom - Vitiligo Market (Million US$), 2012 - 2017

Figure 7 4: United Kingdom - Forecast for Vitiligo Market (Million US$), 2018 - 2024

Figure 8 1: France - Vitiligo Patients Population (Thousand), 2012 - 2017

Figure 8 2: France - Forecast for Vitiligo Patients Population (Thousand), 2018 - 2024

Figure 8 3: France - Vitiligo Market (Million US$), 2012 - 2017

Figure 8 4: France - Forecast for Vitiligo Market (Million US$), 2018 - 2024

Figure 9 1: Germany - Vitiligo Patients Population (Thousand), 2012 - 2017

Figure 9 2: Germany - Forecast for Vitiligo Patients Population (Thousand), 2018 - 2024

Figure 9 3: Germany - Vitiligo Market (Million US$), 2012 - 2017

Figure 9 4: Germany - Forecast for Vitiligo Market (Million US$), 2018 - 2024

Figure 10 1: Italy - Vitiligo Patients Population (Thousand), 2012 - 2017

Figure 10 2: Italy - Forecast for Vitiligo Patients Population (Thousand), 2018 - 2024

Figure 10 3: Italy - Vitiligo Market (Million US$), 2012 - 2017

Figure 10 4: Italy - Forecast for Vitiligo Market (Million US$), 2018 - 2024

Figure 11 1: India - Vitiligo Patients Population (Thousand), 2012 - 2017

Figure 11 2: India - Forecast for Vitiligo Patients Population (Thousand), 2018 - 2024

Figure 11 3: India - Vitiligo Market (Million US$), 2012 - 2017

Figure 11 4: India - Forecast for Vitiligo Market (Million US$), 2018 - 2024

Figure 12 1: China - Vitiligo Patients Population (Thousand), 2012 - 2017

Figure 12 2: China - Forecast for Vitiligo Patients Population (Thousand), 2018 - 2024

Figure 12 3: China - Vitiligo Market (Million US$), 2012 - 2017

Figure 12 4: China - Forecast for Vitiligo Market (Million US$), 2018 - 2024

Figure 13 1: Japan - Vitiligo Patients Population (Thousand), 2012 - 2017

Figure 13 2: Japan - Forecast for Vitiligo Patients Population (Thousand), 2018 - 2024

Figure 13 3: Japan - Vitiligo Market (Million US$), 2012 - 2017

Figure 13 4: Japan - Forecast for Vitiligo Market (Million US$), 2018 - 2024

Figure 14 1: Vitiligo Pipe Line Drug - ARN-4079 Status (2018)

Figure 14 2: Vitiligo Pipe Line Drug - ATI-502 Status (2018)

Figure 14 3: Vitiligo Pipe Line Drug - AX-1602 Status (2018)

Figure 14 4: Vitiligo Pipe Line Drug - BOS-475 Status (2018)

Figure 14 5: Vitiligo Pipe Line Drug - CCP-070 Status (2018)

Figure 14 6: Vitiligo Pipe Line Drug - Cerdulatinib (RVT-502) Status (2018)

Figure 14 7: Vitiligo Pipe Line Drug - HuABC-2 Status (2018)

Figure 14 8: Vitiligo Pipe Line Drug - Abatacept Status (2018)

Figure 14 9: Vitiligo Pipe Line Drug - Topical Ruxolitinib Status (2018)

Figure 14 10: Vitiligo Pipe Line Drug - VLRX-001 Status (2018)

Figure 18 1: Axim Biotechnologies, Inc - Global Sales (US$), 2015 - 2017

Figure 18 2: Axim Biotechnologies, Inc - Forecast for Global Sales (US$), 2018 - 2024

Figure 19 1: Incyte Corporation - Global Sales (Million US$), 2012 - 2017

Figure 19 2: Incyte Corporation - Forecast for Global Sales (Million US$), 2018 - 2024

Figure 20 1: Bristol-Myers Squibb - Global Sales (Million US$), 2012 - 2017

Figure 20 2: Bristol-Myers Squibb - Forecast for Global Sales (Million US$), 2018 - 2024

Figure 21 1: Clinuvel Pharmaceuticals Limited - Global Sales (Thousand US$), 2013 - 2017

Figure 21 2: Clinuvel Pharmaceuticals Limited - Forecast for Global Sales (Thousand US$), 2018 - 2024

List of Tables:

  • Table 15-1: Global - Vitiligo Market Clinical Study, 2018